Anzeige
❌
Mehr »
Dienstag, 06.10.2026 - Börsentäglich über 12.000 News
US-Compliance: Kobalt-Ziele in zwei Ozeanen im Fokus
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 | ISIN: BE0003818359 | Ticker-Symbol: GXE
Xetra
05.10.26 | 17:35
26,400 Euro
+2,48 % +0,640
Branche
Biotechnologie
Aktienmarkt
BEL Mid
AMX
1-Jahres-Chart
LAKEFRONT BIOTHERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
LAKEFRONT BIOTHERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
26,04026,34005.10.
26,08026,30005.10.

Aktuelle News zur LAKEFRONT BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.09.Lakefront Biotherapeutics Stock Rises 4% After Share Repurchase Update4
23.09.TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday1
23.09.RBC stuft Lakefront Biotherapeutics hoch - Potenzial bei Autoimmun-Medikament treibt Kursziel11
23.09.RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential7
LAKEFRONT BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
23.09.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer-
08.09.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer3
01.09.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
25.08.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
24.08.Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America538Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant...
► Artikel lesen
24.08.Lakefront Biotherapeutics: U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus1.412Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted...
► Artikel lesen
21.08.TD Cowen upgrades Lakefront Biotherapeutics stock rating to buy5
12.08.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer-
10.08.Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update1.439Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first...
► Artikel lesen
10.08.Lakefront BioTherapeutics reports Q2 results14
04.08.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer3
21.07.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer3
13.07.Lakefront Biotherapeutics director resigns for Sanofi role20
13.07.Lakefront Biotherapeutics: Direktor tritt für Position bei Sanofi zurück33
13.07.Lakefront Biotherapeutics: Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi536Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research...
► Artikel lesen
10.07.Lakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley2
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1